Proteonomix, Inc. (PROT) Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency

June 7, 2010 |

2 min read

MOUNTAINSIDE, NJ--(Marketwire - June 07, 2010) -

Highlighted Links

Proteonomix, Inc. (PINKSHEETS: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations agency effective immediately.

Michael Cohen, Chairman, President & CEO of Proteonomix, stated, “We’ve retained Wolfe Axelrod Weinberger Associates to assist us in communicating our unique strategy to the financial community to improve investor awareness. We believe an active investor relations program will broaden our investor exposure and we believe that Wolfe Axelrod Weinberger will provide us with seasoned experience in this area.”

Wolfe Axelrod Weinberger Associates brings to its clients thirty years of successful investor relations experience and an extensive network of contacts. Wolfe Axelrod Weinberger Associates looks forward to working closely with Proteonomix, to accomplish its long-term objective of increasing shareholder value.

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromalCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromalCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit www.proteonomix.com, www.proteoderm.com, www.otcqb.com and www.sec.gov.

Forward-looking statements: Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.